The average monthly cost of headache medications prior to BoNT-A treatment was $242.7 (SD 191.4; range: 0 - 864.2).
The average monthly cost of headache medications following BoNT-A treatment was $89.2 (SD 104.1; range: 0 - 405.0). The latter did not include the cost of BoNT-A treatment. This reduction in cost (63.3%) was statistically significant, (p<0.001).
When the cost of BoNT-A treatment was included in the analysis, the average monthly cost post-treatment became $266.1 (SD 126.5; range: 52.1 - 752.5), which was $23.0 higher than the pre-treatment cost. This increase over the pre-treatment cost was not statistically significant, (p=0.052).
The average monthly cost of headache medications prior to BoNT-A treatment was significantly lower for TTH patients ($136.19) than for migraine patients ($264.89), (p=0.001).
After BoNT-A treatment, when the cost of BoNT-A treatment was included in the analysis, the average monthly cost of headache medications was significantly increased for TTH patients ($259.55, SD 97.64; range: 107.56 - 532.48; p<0.001) but not for migraine patients ($256.41, SD 124.56; range: 52.13 - 716.43; p>0.05).
Pre- and post-treatment average monthly costs were calculated based on medication use for the 6 months prior to and following initiation of BoNT-A treatment.
The costs of adverse events were not dealt with in the costing.